Results 211 to 220 of about 1,459,292 (318)

Pharmacokinetic and Pharmacodynamic Drug‐Drug Interactions Between Cofrogliptin and Metformin in Healthy Subjects: A Single‐Center, Single‐Arm, Phase I Study in China

Clinical Pharmacology in Drug Development, Volume 15, Issue 10, October 2026.
Abstract This single‐center, single‐arm, Phase I study evaluated drug–drug interactions (DDIs) between cofrogliptin and metformin in healthy Chinese subjects. Twenty‐two subjects sequentially received metformin monotherapy (Days 1–4), cofrogliptin monotherapy (Days 6–34), and combination therapy (Days 38–47).
Cheng Cui, Na Liu, Chang Chu, Shu Niu, Yang Huang, Fangqiong Li, Yaming Li, Haiyan Li, Dongyang Liu   +8 more
wiley   +1 more source

HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy

AIDS (London), 1998
C. Craig, E. Race, J. Sheldon, L. Whittaker, Susan M. Gilbert, Alec R. Moffatt, J. Rose, S. Dissanayeke, G. Chirn, I. Duncan, N. Cammack   +10 more
semanticscholar   +1 more source

Cross‐Neutralizing and Broadly Neutralizing Human Antibodies Against Nonenveloped Viruses

European Journal of Immunology, Volume 56, Issue 10, October 2026.
In this review article, Marchand et al. compare cross ‐ and broadly ‐neutralizing human antibodies against non ‐ enveloped viruses from several major families, discussing their structural characteristics, neutralization mechanisms and relevance for the development of antiviral vaccines and therapeutics.
Sarah Marchand, Samy Taouli, Dorian McIlroy   +2 more
wiley   +1 more source

Frequency of Metabolic Syndrome in Patients With Hepatitis C Virus Infection: A Cross‐Sectional Study

Health Science Reports, Volume 9, Issue 10, October 2026.
ABSTRACT Background and Aim Metabolic syndrome significantly increases the risk of cardiovascular disease and type 2 diabetes. Hepatitis C virus (HCV) infection has been associated with an increased risk of metabolic syndrome. This study aims to explore this association to improve management strategies for HCV patients at risk of metabolic syndrome ...
Muhammad Awais, Maryam Ilyas, Muhammad Husnain Ahmad, Muhammad Taha Shaukat, Abdul Waheed, Aniqa Iqbal, Muhammad Umar Nadeem, Nimra Mahmood, Ali Gohar, Hamza Zaheer, Ahmed Zia, Masab Ali   +11 more
wiley   +1 more source

HIV protease inhibitors saquinavir and nelfinavir are potent inhibitors of cathepsin L activity: A potential treatment for COVID-19 patients

, 2020
Montenegro MF, Al-Abed Y, He M, Tracey KJ, Billiar TR.   +4 more
europepmc   +1 more source

Predictors of Liver Steatosis Progression Among People Living With HIV in Low‐ and Middle‐Income Countries: A Multicentre Longitudinal Study

Journal of the International AIDS Society, Volume 29, Issue 10, October 2026.
ABSTRACT Introduction Liver steatosis is increasingly recognized as a major comorbidity in people living with HIV (PLWH), with growing evidence suggesting an increased risk of progression to advanced liver disease. We assessed predictors of liver steatosis progression over 36 months in PLWH from low‐ and middle‐income countries.
Marie K. Plaisy, Thierry Tiendrebeogo, Carlotta Mondoka, Mark H. Kuniholm, Rodrigo de Carvalho Moreira, Aggrey Semeere, Rohidas T. Borse, Albert Minga, Gilles Wandeler, Gad Murenzi, Brenda E. Crabtree‐Ramírez, Niharika Samala, Jeremy Ross, Ephrem Mensah, Ardele Mandiriri, Sandra W. Cardoso, Jean Paul Mivumbi, Lameck Diero, Haridas Prasad, Paola Alarcón Murra, Belinda V. Chihota, Suzanne Goodrich, Thida Chanyachukul, Ellen Brazier, Stephany N. Duda, Hugo Perazzo, Antoine Jaquet, the International epidemiology Databases to Evaluate AIDS (IeDEA)   +27 more
wiley   +1 more source

Metabolic Dysfunction‐Associated Steatohepatitis and the Progression of Cognitive Decline in Older Thai People With HIV

Journal of the International AIDS Society, Volume 29, Issue 10, October 2026.
ABSTRACT Introduction Metabolic dysfunction‐associated steatohepatitis (MASH) is more common in people with HIV and associated with systemic inflammation and extrahepatic complications, including cognitive impairment. While cross‐sectional studies suggest an association between MASH and worse cognitive outcomes, its impact on longitudinal cognitive ...
Katekarn Porkaew, Akarin Hiransuthikul, Win Min Han, Tanakorn Apornpong, Sasiwimol Ubolyam, Stephen Kerr, Anchalee Avihingsanon, HIV‐NAT 006 and 207 study team   +7 more
wiley   +1 more source

Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers. [PDF]

Antimicrob Agents Chemother, 2019
Feng HP, Caro L, Fandozzi C, Chu X, Guo Z, Talaty J, Panebianco D, Dunnington K, Du L, Hanley WD, Fraser IP, Mitselos A, Denef JF, De Lepeleire I, de Hoon JN, Vandermeulen C, Marshall WL, Jumes P, Huang X, Martinho M, Valesky R, Butterton JR, Iwamoto M, Yeh WW.   +23 more
europepmc   +1 more source

Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport

AIDS (London), 2001
K. Jones, P. Hoggard, S. D. Sales, S. Khoo, R. Davey, D. Back   +5 more
semanticscholar   +1 more source

Malassezia May Contribute to Basal Cell Carcinoma Development via Inflammatory and Oxidative Stress Pathways

MicrobiologyOpen, Volume 15, Issue 5, October 2026.
Malassezia (predominantly M. globosa) colonizes BCC tissues. In vitro fungal stimulation accelerates epithelial proliferation and modulates inflammatory/oxidative stress cascades potentially relevant to BCC biology. ABSTRACT Basal cell carcinoma (BCC) is the most common malignant skin tumor.
Xiaolei Zhu, Wen Zhang, Tinghong Ye, Heng Zhang, Jufang Tan, Yi Sun   +5 more
wiley   +1 more source